Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M

Key Points

• Brookline Cap M raised its Q1 2026 EPS estimate for Perspective to ($0.31) from ($0.44) and now forecasts FY2026 EPS of ($1.27), versus the market consensus of ($0.88).
• Perspective reported Q1 EPS of ($0.51) on just $0.04 million in revenue, with a negative return on equity of 41.79% and an extreme net margin of -11,665.27%, highlighting its loss-making position.
• Sell‑side sentiment is broadly positive—multiple firms have raised price targets and most rate the stock a "Buy" (consensus target $12.50)—and institutional investors own about 54.66% of the shares.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) - Stock analysts at Brookline Cap M lifted their Q1 2026 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research note issued to investors on Tuesday, March 17th. Brookline Cap M analyst K. Dolliver now anticipates that the company will earn ($0.31) per share for the quarter, up from their prior estimate of ($0.44). The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Brookline Cap M also issued estimates for Perspective Therapeutics' Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.27) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last posted its earnings results on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. The business had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.

CATX has been the subject of several other research reports. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday. BTIG Research reaffirmed a "buy" rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday. B. Riley Financial lifted their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday. HC Wainwright boosted their price target on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, January 30th. Finally, UBS Group upped their price objective on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $12.50.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $4.86 on Thursday. The company has a current ratio of 5.17, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16. The firm's 50 day moving average is $4.30 and its two-hundred day moving average is $3.43.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently modified their holdings of the business. Opaleye Management Inc. acquired a new position in Perspective Therapeutics in the fourth quarter valued at $3,257,000. Patient Square Capital LP boosted its stake in shares of Perspective Therapeutics by 224.3% during the fourth quarter. Patient Square Capital LP now owns 1,132,815 shares of the company's stock worth $3,115,000 after buying an additional 783,492 shares during the period. Bank of America Corp DE boosted its stake in shares of Perspective Therapeutics by 139.9% during the third quarter. Bank of America Corp DE now owns 785,823 shares of the company's stock worth $2,695,000 after buying an additional 458,323 shares during the period. Marshall Wace LLP purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth about $1,119,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company's stock worth $2,573,000 after buying an additional 405,612 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: B. Riley raised its price target from $11 to $13 and maintained a "Buy" rating — a sizeable upside projection that signals stronger sell‑side conviction in the company's growth/clinical roadmap. B. Riley Price Target Raise
• Positive Sentiment: UBS raised its price target from $7 to $8 and kept a "Buy" rating, providing additional analyst support for upside potential. UBS Price Target Raise
• Positive Sentiment: Wedbush reaffirmed its "Outperform" rating with an $11 target — another vote of confidence from a major biotech analyst. Wedbush Rating Reaffirmation
• Positive Sentiment: Perspective announced that updated data for its lead radiopharmaceutical, [212Pb]VMT-α-NET, was accepted for poster presentation at AACR 2026 — this raises scientific visibility and could help commercial/regulatory momentum if the data remain favorable. The company previously reported encouraging anti‑tumor activity (76% without progression in a subset) and no dose‑limiting toxicities in interim analyses. AACR Presentation Acceptance
• Neutral Sentiment: The company is scheduled to release quarterly earnings this week — an event that can be a catalyst for volatility as investors reassess cash runway, R&D spend and trial progress. Earnings Release Date
• Neutral Sentiment: Perspective published full‑year 2025 results and business highlights; these filings provide more detail on cash, operating burn and program timelines that investors will parse for runway and dilution risk. Full‑Year 2025 Results
• Negative Sentiment: Royal Bank of Canada trimmed its target from $18 to $14 (still "Outperform") — a downward revision that could moderate upside expectations and trigger short‑term profit‑taking. RBC Target Lowered
• Negative Sentiment: Clinical safety data include Grade 3+ treatment‑emergent adverse events in ~37.5% of patients (one transient Grade 4 reported); these safety signals may temper enthusiasm until larger cohorts and confirmatory data are available. Clinical Safety Details

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.